¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ [5/26] WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ (COVID-19 Global Epidemiological Update )
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 

 

[5/26]

WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ

(COVID-19 Global Epidemiological Update )

 

Coronavirus Disease 2019 (COVID-19) µ¿Çâ Highlights



 

¼¼°èº¸°Ç±â±¸ COVID-19 Highlights

 

ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²(2020.0526) 

ÇöÀç Àü¼¼°èÀûÀ¸·Î 214°³±¹¿¡¼­ COVID-19·Î ÀÎÇÑ È®ÁøÀÚ´Â 5,304,772¸í, »ç¸ÁÀÚ ´Â 342,029¸íÀ¸·Î ÇöÀç±îÁö Ä¡¸íÀ²(CFR)Àº 6.45%¸¦ ³ªÅ¸³»°í ÀÖ´Ù.  ¼¼°èº¸°Ç±â±¸(WHO)¿¡ ÀÇÇÑ ÁÖ¿ä Áö¿ªº° È®ÁøÀÚ ¹× Ä¡¸í·ü(CFR)Àº ¾Æ·¡¿Í °°´Ù.  

 

Ç¥ 1 ) ¼¼°è Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Situation Report-126)

[Globally ÃÑ È®ÁøÀÚ 5,304,772¸í(½Å±Ô 100 264),  »ç¸ÁÀÚ 342,029¸í(½Å±Ô 4,342¸í) ]

±¸ºÐ

À¯·´

¾Æ¸Þ¸®Ä«

µ¿ºÎÁöÁßÇØ

¼­ÅÂÆò¾ç

µ¿³²¾Æ½Ã¾Æ

¾ÆÇÁ¸®Ä«

È®ÁøÀÚ(¸í)

2,025176

2,395,295

427,832

174,548 

201,207

80,002

»ç¸ÁÀÚ(¸í)

174,429

141,472

11,164

6,879

5,952

2,120

Ä¡¸í·ü(CFR)

8.61%

5.91%

2.61%

3.94%

2.96%

2.65%





 

±×¸² 1) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â5¿ù26ÀÏÀÚ WHO º¸°í) 

Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report -126 [¹Ù·Î°¡±â]




 

Ç¥ 2) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â5¿ù18ÀÏÀÚ WHO º¸°í)

       Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 126






 

±×¸² 3) COVID-19 È®Áø ¿ªÇа(³¯Â¥º°, Áö¿ªº° 2020³â 5¿ù25ÀÏÀÚ)

 Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 119 [¹Ù·Î°¡±â]






 

[Ãֽŵ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights

 

F1. [±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma) 

±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼­ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼­ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]



 

F2. COVID-19 Ä¡·áÁ¦ ±ÝÁö :À̺ÎÇÁ·ÎÆæ(Ibuprofen), ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs) 

ÀÇÇÐ Àú³Î ¶õ¼Â(The Lancet Respiratory Medicine)Àº À̺ÎÇÁ·ÎÆæÀ» Æ÷ÇÔÇÑ ÀϺΠ¾àÇ°ÀÌ °íÇ÷¾ÐÀ̳ª ´ç´¢º´À» ¾Î´Â COVID-19 ȯÀÚ¿¡°Ô À§ÇèÇÒ ¼ö ÀÖ´Ù´Â °¡¼³À» ¹ßÇ¥Çß´Ù. À̺ÎÇÁ·ÎÆæÀº ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁøÅëÁ¦·Î, ÁøÅëÁ¦³ª ÇØ¿­Á¦·Îµµ ¾²ÀδÙ. ‘¶õ¼Â È£Èí±âÀÇÇÐ(Lancet Respiratory Medicine)’¿¡¼­ ¸¶ÀÌŬ ·Î½º(Michael Roth) ¹ÙÁ©ÀÇ´ë ±³¼ö´Â À̺ÎÇÁ·ÎÆæÀ» º¹¿ëÇϸé COVID-19ÀÇ ÁÖ¿ä ħÅõ °æ·ÎÀΠǥÀû ´Ü¹éÁú ACE2°¡ ¼¼Æ÷¿¡ °ú´Ù ¹ßÇöµÅ COVID-19ÀÇ ÁßÁõµµ ¶Ç´Â °¨¿° À§ÇèÀ» ³ôÀÏ ¼ö ÀÖÀ½À» ¹àÇû´Ù. [»ó¼¼º¸±â]



 

F3. COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ

½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼­´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù.  [»ó¼¼º¸±â]

 

F4. NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]

 

º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á-  Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù. 

 

º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.

 

1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)

2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)

3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79) 

4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)

5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40) 

6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)

¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼­ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]

F 5. COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ

ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼­ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °­·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]



 

Ç¥ 3)  Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â  

±¹¿Ü ±â°ü

»çÀÌÆ®

JAMA

https://jamanetwork.com/journals/jama/pages/coronavirus-alert

The Lancet

https://www.thelancet.com/coronavirus

NEJM

https://www.nejm.org/coronavirus

Cambridge University Press

https://www.cambridge.org/core/browse-subjects/medicine/coronavirus-free-access-collection#

Centers for Disease Control and Prevention

https://www.cdc.gov/coronavirus/index.html

WHO 

https://www.who.int/westernpacific/emergencies/novel-coronavirus

Elsevier

https://www.elsevier.com/connect/coronavirus-information-center

Cochrane

https://www.cochranelibrary.com/collections/doi/SC000039/full

Karger

https://www.karger.com/Tap/Home/278492

Oxford University Press

https://global.oup.com/academic/category/medicine-and-health/coronavirus/?cc=us&lang=en&A

Science

https://www.sciencemag.org/tags/coronavirus

Springer

https://www.springernature.com/gp/researchers/campaigns/coronavirus

Wiley Library

https://novel-coronavirus.onlinelibrary.wiley.com/

Wolters Kluwer

http://healthclarity.wolterskluwer.com/coronavirus-resources.html

The Scientist

https://www.the-scientist.com/tag/coronavirus

Taylor & Francis Group

https://newsroom.taylorandfrancisgroup.com/coronavirus-reading-list/#




 

Ç¥4) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü ÃÖ±Ù ¾÷µ¥ÀÌÆ® Á¤º¸ ¹Ù·Î°¡±â






 

      ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø









 

References

WHO, Coronavirus disease 2019 (COVID-19) Situation Report 119 (May 25, 2020)  [¹Ù·Î°¡±â]

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (May 01, 2020). The New England Journal of Medicine [¹Ù·Î°¡±â]

 

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults With Coronavirus Disease 2019 (COVID-19) [¿ø¹®º¸±â]

WHO Officials Discuss the Weather Question (March 05, 2020) [¹Ù·Î°¡±â]  

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC). COVID-19 outbreak: Comparison of: SARS, MERS  (March 05, 2020). [¹Ù·Î°¡±â

Will Warm Weather Curb Coronavirus? What the Experts Say,  Ari Altstedter & John Lauerman (March 12, 2020), Bloomberg Quicktake  [¹Ù·Î°¡±â

Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases --- United States and Worldwide, December 2003 [¹Ù·Î°¡±â]  

JAMA COVID-19 Resource Center, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention JAMA. Published online February 24, 2020. [¹Ù·Î°¡±â]   

¸Þ¸£½º (Middle East Respiratory Syndrome Coronavirus: MERS) Áúº´°ü¸®º»ºÎ [¹Ù·Î°¡±â]   

WHO, Severe Acute Respiratory Syndrome (SARS). [¹Ù·Î°¡±â]   

WHO, Coronavirus, [¹Ù·Î°¡±â]  

The New York Times How Bad Will the Coronavirus Outbreak Get? Here Are 6 Key Factors [¹Ù·Î°¡±â]

 

 


 


2020-05-26 ¿ÀÈÄ 5:24:03, Á¶È¸¼ö : 2790